A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD. Carpenter, P., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., Abonour, R., Westervelt, P., Dansey, R., Richard, S., Jerome, K., Corey, L., Anasetti, C. AMER SOC HEMATOLOGY. 2003: 712A

View details for Web of Science ID 000186536702634